Freeze-Thaw Stability Investigation Service for Antibody Formulation
Introduction
Freezing is a standard and critical step in the manufacturing and storage of biopharmaceuticals like monoclonal antibodies (mAbs). It provides a longer shelf life, reduces the risk of microbial growth, and offers flexibility by decoupling drug substance manufacturing from final product fill-finish. However, the physical and chemical stresses of freeze-thaw (F/T) cycles can cause irreversible changes, leading to protein aggregation, loss of activity, and potential immunogenic reactions. A lack of understanding of the underlying mechanisms can lead to a non-optimized approach, which negatively impacts product quality and increases overall development costs and time. Our service provides the essential knowledge to develop a stable and scalable formulation.
Methodologies
A well-characterized F/T process is a key part of a robust supply chain, providing flexibility for clinical and commercial demands. Developing a robust formulation for F/T stability requires a multi-faceted approach. We use a combination of complementary and orthogonal analytical methods to evaluate an antibody's properties and stability at both small and large scales.
- Small-Scale Modeling: Early in development, small-scale models are used to systematically evaluate key variables such as F/T rates, temperatures, and excipient concentrations. This approach helps identify a molecule's susceptibility to stress factors and provides a framework for scaling up manufacturing.
-
Analytical Techniques: We employ a comprehensive suite of techniques to monitor various aspects of stability:
- Size Exclusion Chromatography (SEC): This is a primary method used to detect and quantify protein aggregates and fragments.
- Dynamic Light Scattering (DLS): A non-invasive technique that measures particle size and helps detect aggregation.
- Differential Scanning Calorimetry (DSC): Measures the thermal stability of a protein, providing insights into its unfolding behavior.
- Circular Dichroism (CD): Used to assess changes in a protein's secondary structure after F/T cycles or in the presence of excipients.
- Surface Plasmon Resonance (SPR): Provides high-quality data on molecular interactions to confirm that a formulation does not negatively impact an antibody's binding affinity or specificity.
- Excipient and Formulation Screening: We systematically screen and select appropriate excipients, including buffers (e.g., histidine, sodium phosphate) to maintain a stable pH, surfactants (e.g., polysorbates) to reduce interfacial stress, and cryoprotectants (e.g., sucrose, trehalose) to prevent aggregation. The goal is to identify an optimal formulation that is stable, scalable, and compatible with the container-closure system.
Our Antibody Formulation Development Service for Freeze-Thaw Stability
The F/T process is crucial for maintaining the quality and stability of bulk drug substances during long-term storage and transportation. It also enables the storage of process intermediates between manufacturing steps, allowing for longer hold times. In a clinical context, stable formulation is essential for in-use stability studies, ensuring that a product remains safe and efficacious after being diluted for intravenous (IV) administration. By providing a stable product, manufacturers can reduce the risk of clinical delays and stock-outs.
Our service provides a clear, professional, and data-driven pathway to a robust and stable formulation, enabling a seamless transition from development to large-scale manufacturing.
Contact Us
At Creative Biolabs, our Antibody Formulation Development Service for Freeze-Thaw Stability is built on a foundation of scientific rigor, deep expertise, and a commitment to data-driven solutions. Our approach ensures that you not only get a stable product but also a profound understanding of the underlying molecular mechanisms driving its stability.
FAQs
Why is freeze-thaw stability testing so important?
Freeze-thaw cycles are common during manufacturing, transport, and storage, and can cause significant protein aggregation and degradation, impacting a product's safety and efficacy. Our service helps you proactively identify and mitigate these risks, ensuring your product's quality and preventing costly failures.
What is the main cause of freeze-thaw instability?
The primary cause is the stress induced by the formation of ice-water interfaces and cryoconcentration. As water freezes, solutes and proteins become concentrated, which can lead to pH shifts and increased protein-protein interactions, causing aggregation. This is especially problematic during slow thawing, which prolongs the exposure to these highly concentrated, destabilizing conditions.
Is there an optimal temperature for frozen storage?
The safest long-term storage temperature is typically well below the formulation's glass transition temperature (Tg′), such as at -80°C. However, our service can identify formulations and F/T protocols that provide stability at more convenient temperatures like -20°C, helping to reduce your cold chain costs.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
